You are here

Article Text

Article menu
Download PDFPDF
Editorial commentary
Use of screening blood tests in patients with carpal tunnel syndrome
  1. Jeremy D P Bland
  1. Correspondence to:
 Dr Jeremy D P Bland
 East Kent Hospitals NHS Trust, Neurophysiology, EEG Department, Ethelbert Road, Canterbury CT1 3NG, UK; jbland{at}cix.compulink.co.uk

http://dx.doi.org/10.1136/jnnp.2006.108647

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Is it is worth performing screening investigations in patients with carpal tunnel syndrome without clinical evidence of other diseases?

    Carpal tunnel syndrome (CTS) has a fair claim to being the world’s commonest neurological disorder. The way in which it is investigated and treated has substantial economic consequences. One aspect of this is addressed by de Rijk and colleagues1 in this issue of the journal—the utility of screening blood tests in patients with CTS (see p 635). The suggestion that such investigation may not be worthwhile is not new.2 Screening is predicated on the belief that CTS is often secondary to medical disease and CTS …

    View Full Text

    Footnotes

    • Competing interests: None.

    Linked Articles